Gilead CEO on FDA Approval of Injectable HIV Prevention: A New Era

A Milestone in HIV Prevention

• 🚀 Yeztugo, Gilead's new injectable medication, has received FDA approval, marking a significant advancement in HIV prevention.
• 💡 This first-of-its-kind medicine is administered twice a year, offering nearly 100% protection against HIV in clinical trials.
• ✨ Developed over 20 years by Gilead scientists, it is considered one of the most important scientific breakthroughs for potentially ending the HIV epidemic.

Addressing Pill Adherence Challenges

• 💊 While pills are available, adherence is a major issue, with only about 50% of people compliant, leading to potential breakthrough cases.
• 🎯 The injectable format aims to meet people where they are, simplifying prevention by requiring clinic visits only every six months.
• ⚠️ This is crucial given that approximately 30,000 new HIV infections occur annually in the United States and 1.3 million worldwide.

Public Health Crisis and Disparities

• 📈 HIV rates are disproportionately rising in certain regions, particularly the Southern United States (Texas, Louisiana, Georgia, Florida), impacting women, Black, and Latino men.
• 💔 Sadly, about 100 people die from HIV-related illnesses weekly in the US, highlighting the ongoing public health crisis.
• 🌍 Gilead emphasizes the global nature of the epidemic, stating that stopping the virus everywhere is essential.

Cost, Access, and Global Strategy

• 💰 The price of Yeztugo is set in line with other branded PrEP medicines, with a typical patent protection of 12-15 years.
• 🤝 Gilead has established licensing agreements with six generic manufacturers to provide the medicine to over 120 low and middle-income countries, working with global aid organizations during the transition.
• 🏥 Most existing PrEP medicines are covered by insurance (over 90%), and Gilead offers programs for the uninsured and co-pay assistance.

Future of HIV Prevention Access

• ⚖️ The potential impact of a Supreme Court case that could overturn insurance coverage requirements for preventative measures is discussed, though Gilead remains committed to ensuring access.
• 🗣️ The motivation for an injectable is different from daily pills; users seek an intervention they can "forget about" for six months, focusing on protection rather than daily management.